Moderna (MRNA) Q4 2024 Earnings Call Transcript
Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...
Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Hosted on MSN20h
Moderna’s (NASDAQ:MRNA) Q4 Earnings Results: Revenue In Line With Expectations But Full-Year Sales Guidance Misses Expectations Significantly
Biotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other ...
AIM Vaccine Leverages AI to Advance mRNA Vaccine Development mRNA Shingles Vaccine Submits Clinical Trial Application
AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA shingles vaccine has been submitted for ...
IFLScience4d
Montana Considers Becoming First US State To Ban mRNA Vaccine Use
Laura is an editor and staff writer at IFLScience. She obtained her Master's in Experimental Neuroscience from Imperial College London.